Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus

Irene Carrión Barberà
,
Laura Triginer
ORCID logo ,
Laura Tío
* ORCID logo ,
Carolina Pérez-García
,
Andrea Toloba
,
Ana Ribes
,
Victoria Abad
,
Ana Pros
,
Marcelino Bermudez
ORCID logo ,
Eva Castro-Boqué
,
Albert Lecube
,
José Valdivielso
ORCID logo ,
Jordi Monfort
,
Tarek Carlos Salman-Monte
Version 1 : Received: 31 January 2024 / Approved: 1 February 2024 / Online: 2 February 2024 (04:49:33 CET)

A peer-reviewed article of this Preprint also exists.

Carrión-Barberà, I.; Triginer, L.; Tío, L.; Pérez-García, C.; Ribes, A.; Abad, V.; Pros, A.; Bermúdez-López, M.; Castro-Boqué, E.; Lecube, A.; Valdivielso, J.M.; ILERVAS Project Group; Monfort, J.; Salman-Monte, T.C. Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus. Int. J. Mol. Sci. 2024, 25, 3022. Carrión-Barberà, I.; Triginer, L.; Tío, L.; Pérez-García, C.; Ribes, A.; Abad, V.; Pros, A.; Bermúdez-López, M.; Castro-Boqué, E.; Lecube, A.; Valdivielso, J.M.; ILERVAS Project Group; Monfort, J.; Salman-Monte, T.C. Role of Advanced Glycation End Products as New Biomarkers in Systemic Lupus Erythematosus. Int. J. Mol. Sci. 2024, 25, 3022.

Abstract

Introduction: Advanced glycation end-products (AGEs) may play a relevant role as inducers in the chronic inflammatory pathway present in immune-mediated diseases, such as systemic lupus erythematosus (SLE). AGEs concentrations have been associated, with discrepant results to date, with some parameters such as disease activity or accrual damage, suggesting their potential usefulness as biomarkers of the disease. Objectives: To confirm differences in AGEs levels measured by cutaneous autofluorescence between SLE patients and healthy controls (HC) and study their correlation with various disease parameters. Methods: Cross-sectional study, where AGEs levels were measured by skin autofluorescence, and SLE patients’ data were compared with those of sex- and age-matched HC in a 1:3 proportion through a multiple linear regression model. Correlations of AGEs levels with demographic and clinical data were analyzed through ANOVA tests. Both analyses were adjusted for confounders. Results: AGEs levels in SLE patients were significantly higher than in HC (p<0.001). We found statistically significant positive correlation with SLE disease activity index (SLEDAI) and damage index (SDI), physician and patient global assessment, C-reactive protein, leukocyturia, complement C4, IL6 and oral ulcers. We also found a negative statistically significant correlation with current positivity of anti-nuclear and anti-Ro60 antibodies. Conclusions: AGEs seem to have a role in LES pathophysiology, becoming a new management and prognosis biomarker in this disease. The association with specific antibodies and disease manifestations may indicate a specific clinical phenotype related to higher AGEs levels.

Keywords

Systemic lupus erythematosus; Advanced glycation end products; Cardiovascular disease; Biomarkers

Subject

Medicine and Pharmacology, Immunology and Allergy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.